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patients who recover to their pre-hospitalization EPO dose, post-hospitalization
ESA dose increases frequently persist for several months, possibly due to
missed ESA doses, lower Hb from hospital-related phlebotomy, or increased
inflammatory states post-hospitalization. Strategies to address the causes of
this should be evaluated.
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OBJECTIVES: US dialysis centers typically dose ESA at every session (3x/wk), en-
abling frequent titrations. A once-monthly ESA is currently under FDA consider-
ation. We recently demonstrated that more frequent Hb measurements and dose
titrations are associated with higher ESA utilization. We developed an economic
model to quantify the potential impact of switching from a 3x/wk ESA to one dosed
monthly, due to fewer titrations and fewer Hb measurements, not considering
other efficiencies (e.g., reduced administrations). METHODS: A cost-offset model
estimated total ESA utilization and cost for monthly vs. 3x/wk dosing. Utilization
inputs were derived from a retrospective study of prevalent ( 120 days), adult (
18 years old) hemodialysis patients (n78,730), dialyzing at a large dialysis organi-
zation between 01/01/09-12/31/10. Patients dosed 3x/wk experience 1.1 dose titra-
tions and 2.9 Hb measurements on average per patient-month. Each additional
monthly dose titration is associated with a 24.1% (95% CI: 21.5%-26.4%) increase in
total ESA dose. Based on once-monthly ESA vs. 3x/wk ESA data (Provenzano et al.,
ASN 2011), we projected patients on a once-monthly ESA would experience 0.8
titrations and 1 Hb measurement per month, and projected savings-based reduc-
tions ofmean titrations and tests. Price (derived from published sources), dose and
clinical equivalence were assumed across ESAs. Model outcomes include incre-
mental utilization and cost. RESULTS: The model predicts that switching patients
to monthly ESA could result in a 7.95% (95% CI; 7.10%–8.73%) reduction in per-
patient/month ESA utilization. This translates into savings of 5,322 (95% CI; 4,748–
5,839 U) ESA units/month/patient and $52.37 (95% CI; $46.72–$57.46) per-patient/
month. For an average facility (96 patients), we estimated ESA savings of 510,934
U/month and cost savings of $5,028/month. CONCLUSIONS: The model predicts
that increasing the interval between ESA dose adjustments, based upon the FDA
approval and administration of a once monthly ESA, could decrease ESA utiliza-
tion.
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HOW COMMON IS CO-OCCURRING ED AND BPH IN A HEALTH CARE CLAIMS
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OBJECTIVES: in themedical literature of co-occurrence of erectile dysfunction (ED)
and benign prostatic hyperplasia (BPH) in men range from 20 to 80% depending on
age, definition and severity of symptoms, and other patient characteristics studied.
This study identifies the co-occurrence of these conditions, using healthcare insur-
ance claims data, to provide payers with an estimate of these burdensome
conditions. METHODS: Patients with ED and/or BPH were identified by diagnostic
codes in the Thomson Reuters MarketScan® Database from January 1, 2007 to June
30, 2010. Patients in the samplewere categorized as having BPH, ED, or co-occurring
BPH and ED, and were examined by age group (younger men aged 40-64 and older
men 65 and above). RESULTS: Of 685,270 men who met eligibility criteria, 531,486
(77.6%) were younger men and 153,784 (22.4%) were older men. Overall, 416,228
(60.7%) were diagnosed with ED (mean age 52.5), 336,432 (49.1%) were diagnosed
with BPH (mean age 62.5), and 67,390 (9.8%) were diagnosed with both ED and BPH
(mean age 60.3) in the study period. Among youngermen, co-occurring ED and BPH
accounted for 9.1% inmenwith ED or BPH, 13.4% inmenwith ED and 21.9% inmen
with BPH. Among older men, co-occurring ED and BPH accounted for 12.5% in men
with ED or BPH, 34.3% inmenwith ED, and 16.5% inmenwith BPH. CONCLUSIONS:
In this analysis, co-occurring ED and BPH varied in men by age. In younger men,
co-occurring ED and BPH accounted for a greater percentage of those in the BPH
cohort, whereas, in oldermen, co-occurrence accounted for a greater percentage of
the ED cohort. This may be a reflection of coding in the claims data or may suggest
that men may not seek treatment for both conditions or prioritize conditions dif-
ferently as they age.
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OBJECTIVES: The CMS dialysis prospective payment system (PPS) uses patient
characteristics and comorbidities to calculate payments. The final list of multipli-
ers (case-mix adjusters; CMAs) was effective January 2011. We assessed patient
CMAs and their relationship to ESA and other resource utilization covered by the
PPS. METHODS: We conducted a retrospective analysis of adult (3 18 yrs old) he-
modialysis patients at a large dialysis organization from 1/1/2011-6/30/2011. Pa-
tient CMAs, ESA utilization, other bundled costs (IV medications and laboratory
tests), and number of sessions attendedwere assessed for associationwith the PPS
composite CMA. Differences in utilization were assessed in a stratified generalized
linear model analysis across all months. Outlier payments were added to the base-
payment for very high-cost patients. RESULTS: CMA values were strongly posi-
tively associated with per-session ESA utilization and per-session costs for other
bundle components (p 0.001). ESA dose was 1.24 times higher for patients in the
highest CMA category (1.5) relative to patients in the lowest CMA category (1.0).
Patients in the lowest CMA category had mean additional bundled costs of $8.76
and patients in the highest category had a cost of $11.99 dollars (p 0.001). CMA
valueswere inversely associatedwith number of attended sessions (11.75 attended
sessions in the lowest CMA group vs. 10.16 in the highest; p 0.001). ESA use
accounted for the highest proportion of total costs (0.598). CONCLUSIONS: This
study shows a strong association between CMAs and ESA utilization, additional
treatment costs, and missed sessions. Monthly average CMA values cluster tightly
around 1.0, indicatingmost patients donot qualify for CMS-definedCMAs; however
the strong association between CMA and resource utilization suggests an associa-
tion between the CMA level and patients’ treatment cost , therefore CMS should
implement processes to help dialysis providers gain access to the underlying CMA
conditions and diagnoses.
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OBJECTIVES: To provide a cost-effectiveness analysis of treatments for moderate
grade vesicoureteral reflux (VUR), an illness that accounts for an estimated $100
million in healthcare expenditures. Treatment options include antibiotics, nonsur-
gical endoscopic injection with dextranomer/hyaluronic acid, and surgical repair.
METHODS:A systematic review usingMEDLINE (search terms VUR, treatment, and
cost) for 2006- 2011. RESULTS: Dextranomer/hyaluronic acid injection is the more
cost-effective option compared to ureteral reimplantation when success rates for
dextranomer/hyaluronic acid injection are 58% per ureter for patients with unilat-
eral reflux and 75% per ureter for bilateral reflux. If increasing grades of reflux
require increasing volumes of dextranomer/hyaluronic acid, success rates of 73%
for unilateral reflux and 94% for bilateral reflux represent the break-point for cost-
effectiveness. In models where dextranomer/hyaluronic acid injection is repeated
if VUR does not resolve after initial injection, break-even success rates are 11% and
60% with unilateral reflux if success rates of initial injections were 70% and 55%,
respectively. Break-even success rates for second dextranomer/hyaluronic acid
injections are 29% and 77% per ureter with bilateral reflux, if success rates of initial
injections are 70% and 55%, respectively. Based on 2011 epidemiologic estimates of
5580 children who are candidates for VUR treatments, dextranomer/hyaluronic
acid injection endoscopic injections and clinical outcome success rates as reported
in recent studies, potential annual savings with dextranomer/hyaluronic acid
range from $1.5 million to $23 million. CONCLUSIONS: A nonsurgical approach is
potentially associated with beneficial outcomes and cost-effectiveness. Longer-
term studies are needed to refine the range of outcomes and downstream costs.
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OBJECTIVES: Testing the validity of ICD-9-CM codes to identify diabetic patients
with stage 3-5 chronic kidney disease (CKD) in claims data. METHODS: We con-
ducted a cross-sectional study using claims from a large commercial health plan.
Patients meeting the following criteria were included: 1) diagnosis of type 2 diabe-
tes; 2) 12 months of continuous health plan eligibility; and 3) 2 non-zero serum
creatinine lab values, at least 90 days apart, between January 1, 2004 and June 30,
2011.We identified 12 ICD-9-CM code groups potentially indicative of CKD stage 3-5
and validated them against a “gold standard”, defined as two laboratory claims, at
least 90 days apart, with an estimated glomerular filtration rate (eGFR) 60 mL/
min. eGFR was calculated using the CKD Epidemiology Collaboration equation and
the Modification of Diet and Renal Disease (MDRD) equation. We calculated sensi-
tivity, specificity, positive predictive value (PPV) and negative predictive value for
the selected codes. Exact binomial 95% confidence intervals (CIs) were derived, and
codes with a PPV whose lower CI bound was  80% were considered valid.
RESULTS: The study sample consisted of 383,970 patients. Approximately 16% of
the sample (N61,052) had stage 3-5 CKD based on the “gold standard”. ICD-9-CM
codes for chronic renal failure, stage 3-5 (585.3-5), had a PPV of 84.2% (CI: 83.7% -
85.7%). ICD-9-CM code 585.6, used for end-stage renal disease, had a PPV of 84.7%
(CI: 83.6% - 85.7%). ICD-9-CM code 285.21, used to describe anemia in CKD, had a
PPV of 85.4% (CI: 84.6% - 86.2%). For the remaining code groups, PPV ranged from
50% to 78%, with CIs of  2 percentage points. Similar results were obtained when
eGFR was calculated using the MDRD equation. CONCLUSIONS: This cross-sec-
tional validation study suggests that diabetic patients with stage 3-5 CKD can be
accurately identified in administrative claims data using selected ICD-9-CM codes.
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OBJECTIVES: To evaluate the utility scores from EQ-5D (UK and Thai preference
weight), VAS, and SF-6D in dialysis patients and to compare the correlation be-
tween these scores and the disease specific scores using KDQOL-36. METHODS:
This study was a cross-sectional study. A Face-to-face interviews using EQ-5D and
KDQOL-36 were conducted from April to August 2011 with 160 hemodialysis pa-
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